Voyager Therapeutics Unveils New Preclinical Data

Voyager Therapeutics, a gene therapy developer, Monday reported the publication in Nature Neuroscience of new pre-clinical data from ongoing efforts to develop novel adeno-associated viral capsids (the protein shell of a virus) that efficiently cross the blood-brain barrier and greatly increase the placement of genes into the central nervous system after intravenous administration.

Voyager, which said the results were obtained in a lab operated at the California Institute of Technology (Caltech), noted that new AAV capsids indicated up to a 100-fold increase in the transfer of genes into the central nervous system in a preclinical model compared to the historical standard AAV9. The company said pre-clinical trials underway using the new gene-therapy techniques on non-human primates. Voyager said it obtained a co-exclusive license to the Caltech capsids, intellectual property and related technology in 2016.

Add Comment